Keunchil Park

机构：The University of Texas MD Anderson Cancer Center, Samsung Medical Center, Sungkyunkwan University · ORCID：0000-0002-4846-7449

发表论文 929 篇 · 总被引 75793 次 · h-index 116

代表论文

• Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions (2023 · New England Journal of Medicine · 被引 378)
• First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC (2023 · New England Journal of Medicine · 被引 234)
• Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 (2024 · Journal of Clinical Oncology · 被引 163)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 158)
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial (2024 · Nature Medicine · 被引 134)
• Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial (2023 · Nature Medicine · 被引 109)